FEASIBILITY AND DURABILITY OF PERCUTANEOUS AORTIC VALVE REPLACEMENT: 30-DAY AND ONE-YEAR OUTCOMES  by Maier, Robert M. et al.
A159.E1489
JACC Maarch 9, 2010
Volume 55, issue 10A
 VASCULAR DISEASE
FEASIBILITY AND DURABILITY OF PERCUTANEOUS AORTIC VALVE REPLACEMENT: 30-DAY AND ONE-
YEAR OUTCOMES
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Endovascular Therapy
Abstract Category: Endovascular Therapy
Presentation Number: 1059-373
Authors: Robert M. Maier, Ronald M. Hoedl, Gergana Stoschitzky, Martin Grabenwoeger, Johann Pollak, Stephan Blazek, Dieter Paetzold, Norbert 
Watzinger, Burkert M. Pieske, Olev Luha, Medical University Graz, Graz, Austria, Hospital Hietzing, Vienna, Austria
Background: Percutaneous aortic valve replacement (PAVR) is an emerging alternative treatment option for patients with symptomatic severe 
aortic stenosis (AS) and high risk for operative valve replacement. Beyond feasibility and acute success of the procedure itself, durability of 
hemodynamic results as well as mid-term clinical and echocardiographic follow-up are of major interest.
Methods: 83 patients (30 male, 53 female; mean age 81 ± 6 years) with symptomatic severe AS and a logistic EuroSCORE >20% underwent PAVR 
between May 2007 and September 2009. All procedures were performed in the catheterization laboratory: transfemorally in 81 patients, in two 
patients via a left subclavian approach. After balloon valvuloplasty, the self-expanding CoreValve prosthesis (diameter 26 mm, n = 43; 29 mm, n = 
39) was implanted using the current 18 French delivery catheter system. All patients were scheduled for clinical evaluation and echocardiographic 
follow-up at 30 days and three, six and twelve months after PAVR.
Results: Acute procedural success rate was 98.8%. Echocardiography 30 days after device implantation revealed a significant reduction of peak 
aortic transvalvular pressure gradient (PPG: 99 ± 28 vs. 20 ± 6 mmHg, p <0.0001) and mean pressure gradient (MPG: 59 ± 16 vs. 11 ± 3 mmHg, p 
<0.0001), and a significant increase of calculated aortic valve area (AVA: 0.5 ± 0.1 vs. 1.4 ± 0.2 cm2, p <0.0001). Six patients (7.2%) died within 
the first 30 days, another nine patients (10.8%) deceased up to twelve months after PAVR. 32 patients completed the one-year follow-up period so 
far. All of them had an uneventful postprocedural course. Reduction of transvalvular pressure gradients and increase of valve area were maintained 
and not significantly different from 30-day results (PPG 18 ± 7 mmHg, MPG 10 ± 4 mmHg, and AVA 1.5 ± 0.4 cm2).
Conclusions: PAVR with the self-expanding CoreValve bioprosthesis is an emerging alternative therapy for high-risk patients with symptomatic 
severe AS. Complication rate is acceptable and mortality rate lower than predicted by risk calculation. Favourable hemodynamic features of the 
prosthesis yield a beneficial clinical course and remain unchanged at least up to one year after PAVR.
